Spinocerebellar Ataxia Type 11
Summary
Clinical characteristics.
Spinocerebellar ataxia type 11 (SCA11) is characterized by progressive cerebellar ataxia and abnormal eye signs (jerky pursuit, horizontal and vertical nystagmus). Pyramidal features are seen on occasion. Peripheral neuropathy and dystonia are rare. Six families have been reported to date, one each from the UK, Pakistan, France, Germany, Denmark, and China. Age of onset ranged from early childhood to the mid-40s. Life span is thought to be normal.
Diagnosis/testing.
The diagnosis of spinocerebellar ataxia type 11 (SCA11) is established in a proband with a heterozygous pathogenic variant in TTBK2 identified by molecular genetic testing.
Management.
Treatment of manifestations: Management is supportive; there are no known disease-modifying treatments to date. Physiotherapy and assessment for assistive devices for ambulation; occupational therapy, including home adaptations; speech and language therapy for dysarthria and dysphagia; ankle-foot orthotics if required and good foot care for those with neuropathy; treatment per ophthalmologist for vision issues; prism glasses may be helpful for diplopia.
Surveillance: Annual neurologic evaluation; evaluations with physiotherapist, occupational therapist, speech and language therapist, and ophthalmologist as indicated.
Genetic counseling.
SCA11 is inherited in an autosomal dominant manner. The proportion of SCA11 caused by de novo mutation is unknown. Each child of an individual with SCA11 has a 50% chance of inheriting the pathogenic variant. Prenatal diagnosis for at-risk pregnancies is possible if the diagnosis has been established by molecular genetic testing in an affected family member.
Diagnosis
Suggestive Findings
Spinocerebellar ataxia type 11 (SCA11) should be considered in individuals with the following clinical features:
- Progressive cerebellar ataxia
- Abnormal eye signs (jerky pursuit, horizontal and vertical nystagmus)
- Dysarthria
- Pyramidal features (mild-to-moderate lower-extremity hyperreflexia; in very rare cases, a positive Babinski sign or other pyramidal features)
- Swallowing difficulties
Rare findings in SCA11:
- Peripheral neuropathy
- Dystonia
Establishing the Diagnosis
The diagnosis of spinocerebellar ataxia type 11 (SCA11) is established in a proband with a heterozygous pathogenic variant in TTBK2 identified by molecular genetic testing (see Table 1).
Because the phenotype of SCA11 is indistinguishable from many other inherited disorders with ataxia, recommended molecular genetic testing approaches include use of a multigene panel or comprehensive genomic testing.
Note: Single-gene testing (sequence analysis of TTBK2, followed by gene-targeted deletion/duplication analysis) is rarely useful and typically NOT recommended.
- An ataxia multigene panel that includes TTBK2 and other genes of interest (see Differential Diagnosis) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. Of note, given the rarity of SCA11, some panels for ataxia may not include this gene. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
- Comprehensive genomic testing (which does not require the clinician to determine which gene[s] are likely involved) is another good option. Exome sequencing is most commonly used; genome sequencing is also possible.For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.
Table 1.
Gene 1 | Method | Proportion of Probands with a Pathogenic Variant 2 Detectable by Method |
---|---|---|
TTBK2 | Sequence analysis 3 | 6/6 families 4 |
Gene-targeted deletion/duplication analysis 5 | Unknown 6 |
- 1.
See Table A. Genes and Databases for chromosome locus and protein.
- 2.
See Molecular Genetics for information on allelic variants detected in this gene.
- 3.
Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.
- 4.
Houlden et al [2007], Bauer et al [2010], Lindquist et al [2017], Deng et al [2019]
- 5.
Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.
- 6.
No data on detection rate of gene-targeted deletion/duplication analysis are available.
Clinical Characteristics
Clinical Description
To date, 28 individuals from six families have been identified with a pathogenic variant in TTBK2 [Houlden et al 2007, Bauer et al 2010, Lindquist et al 2017, Deng et al 2019]. The following description of the phenotypic features associated with this condition is based on these reports.
Table 2.
Feature | Number of Persons w/Feature | Comment |
---|---|---|
Cerebellar ataxia | 28/28 | Variable truncal &/or gait ataxia |
Limb ataxia | 21/28 | |
Dysarthria | 22/28 | |
Jerky pursuit | 18/28 | |
Nystagmus | 20/28 | |
Ophthalmoplegia | 2/28 | |
Diplopia | 4/28 | |
Hyperreflexia | 18/28 |
|
Extrapyramidal features | 1/28 |
|
Onset. In the six families described with spinocerebellar ataxia type 11 (SCA11), age of onset ranged from age nine years in the family of Danish origin to age 40-50 years in the families from France, Germany, and China. Most individuals present with a pure ataxia phenotype, with few additional features. Abnormal eye findings were identified in a third of individuals, a small proportion of whom presented with diplopia at onset.
Ataxia. The cerebellar ataxia was clinically similar in all six families. All individuals presented with an ataxia-predominant disorder and difficulty walking due to unsteadiness and maintaining balance. In approximately a third of individuals, limb ataxia was also present. Ataxia was usually slowly progressive. For example, in the British family described, the mean disease duration was 26.8 years [Houlden et al 2007].
Abnormal eye findings include jerky pursuit and horizontal and vertical nystagmus. All of the individuals with SCA11 from Devon had abnormal eye movements at presentation, with jerky pursuit and vertical nystagmus more prevalent than horizontal nystagmus [Houlden et al 2007]. Half of the individuals with vertical nystagmus had an upbeat nystagmus [Giunti et al 2012]. Only a very small proportion were found to be symptomatic with ophthalmoplegia and diplopia. No members of the French family had abnormal eye findings. One individual in the German family had oculomotor disturbances with jerky pursuit, gaze-evoked nystagmus, dysmetric saccades, and impaired optokinetic nystagmus on presentation, nine years after symptom onset [Bauer et al 2010]. In the Danish family, one individual presented with diplopia and nystagmus at age nine years [Lindquist et al 2017]. A sib presented at age four years with ataxia and was found to have nystagmus at age nine years [Lindquist et al 2017]. Three individuals of Chinese descent had nystagmus at the time of presentation [Deng et al 2019]. It is unclear if abnormal eye findings progress, but ocular symptoms were the only presenting feature for one individual out of 28 affected. Although abnormal eye findings may be seen at the time of presentation, they are rarely symptomatic.
Pyramidal features exist in varying degrees across the different families. In the British family, mild limb hyperreflexia more prevalent in the upper than the lower limbs (with negative Babinski sign) was found in all but one affected individual [Houlden et al 2007]. In the family from Pakistan, mild-to-moderate hyperreflexia was observed in only two of five affected individuals [Houlden et al 2007]. Only one of the three individuals affected from the Danish family had hyperreflexia [Lindquist et al 2017]. Two of the five individuals of Chinese descent had hyperreflexia [Deng et al 2019]. Reflexes and tone were, however, normal in the German and French families described [Bauer et al 2010].
No other pyramidal signs apart from hyperreflexia were observed in the 28 individuals apart from one individual with upgoing plantar reflexes. This individual from Devon presented with both extrapyramidal and pyramidal signs including spastic gait, hyperreflexia with upgoing plantar reflexes, "no-no" head tremor, and upper-limb tremor with laterocollis [Giunti et al 2012]. No extrapyramidal signs have been described in other individuals.
Bulbar symptoms. Dysarthria and swallowing difficulties are common in individuals with SCA11. Dysarthria as a result of cerebellar dysfunction was moderate to severe in almost all individuals in the families of British and Pakistani origin but was not present at diagnosis [Houlden et al 2007]. In the French family, dysarthria was an early feature [Bauer et al 2010]. Dysarthria was reported to be progressive in individuals in the family of Chinese origin [Deng et al 2019]. Liquid dysphagia was also noted in individuals with SCA11, especially in the families from Devon and China, but was not common at presentation.
Peripheral neuropathy is not a common feature of SCA11. In the British cohort, nerve conduction studies (NCS) and electromyography (EMG) were normal in eight affected subjects [Houlden et al 2007]. One other affected subject had slightly small sensory nerve action potentials at the age of 61 (disease duration 43 years) but without clinically manifesting neuropathy. In the Pakistani, Danish, French, and German families, neuropathy was not seen. In the Chinese family, EMG of the proband showed extensive neurogenic damage. Somatosensory evoked potentials of the lower limbs were abnormal. Generalized neurogenic damage was seen on NCS and EMG of two other affected Chinese individuals, but it is not apparent whether these individuals also presented with neuropathy symptoms clinically.
Other. One individual from Devon presented with laterocollis [Giunti et al 2012]. Dystonia has not been described in other individuals.
Prognosis. SCA11 is slowly progressive with severity ranging from very mild balance problems at disease onset, to severe speech and swallowing problems and ataxia requiring the use of a wheelchair. In affected individuals from the British and Pakistani families, eight of 17 persons required a wheelchair 20 to 30 years after onset. The same was reported in the French and German families, where progression of disease is slow; individuals remained active many years and required a wheelchair decades after onset [Bauer et al 2010]. Life span in individuals with SCA11 is normal; many affected individuals live beyond age 75 years. In nine individuals from the British and Pakistani families, death occurred between ages 55 and 88 years.
Neuroimaging. Brain MRI examination shows mild-to-severe atrophy in both cerebellar hemispheres and the vermis. The brain stem and cerebrum were normal in most individuals [Giunti et al 2012]. Occasionally, atrophy has also been described in the medulla but this was not associated with disease severity [Giunti et al 2012, Deng et al 2019]. In a Danish proband, an 18Ffluorodeoxyglucose positron emission tomography scan showed reduced metabolic activity in the cerebellum and pons, and repeat brain MRI four years later showed worsening cerebellar atrophy with olivopontine atrophy [Lindquist et al 2017].
Neuropathology. Neuropathologic examination of the brain of one affected individual showed marked cerebellar and brain stem loss with Purkinje cell degeneration and abnormal tau deposition in the brain stem and cortex [Houlden et al 2007].
Genotype-Phenotype Correlations
No genotype-phenotype correlations have been identified.
Penetrance
The TTBK2 pathogenic variants in the six families described to date appear to be fully penetrant, although a number of at-risk relatives are younger than the typical age of onset. To date, no non-penetrant pathogenic variants have been identified in older individuals.
Prevalence
Prevalence is unknown but SCA11 is a rare cause of pure spinocerebellar ataxia. It accounts for less than 1% of autosomal dominant ataxia in Europe [Bauer et al 2010]. Pathogenic variants in TTBK2 were identified in six of 238 families with spinocerebellar ataxia [Houlden et al 2007; Bauer et al 2010; Author, personal observation]. A study in Germany of 49 individuals with a family history of ataxia did not identify pathogenic variants in TTBK2 [Edener et al 2009]. A study in China of 68 unrelated probands with autosomal dominant ataxia also did not identify pathogenic variants in TTBK2 [Xu et al 2010].
The six families described with SCA11 are from Devon (UK), Pakistan, France, Germany, Denmark, and China.
Differential Diagnosis
According to AE Harding's classification, spinocerebellar ataxia type 11 (SCA11) is included in the pure autosomal dominant cerebellar ataxias (ADCA III) [Worth et al 1999], the most common group of inherited ataxias. SCA11 accounts for approximately 2% of ADCA III.
Significant overlap is observed between SCA11 and SCA5, SCA6, SCA15, and SCA20, all of which may be distinguished by molecular genetic testing (see Table 3).
Table 3.
Gene | Disorder | MOI | Key Clinical Features |
---|---|---|---|
CACNA1A | SCA6 | AD | Pure cerebellar ataxia w/slow progression. Some described w/downbeat nystagmus, whereas 50% of British individuals w/SCA11 had an upbeat nystagmus. |
ITPR1 | SCA15 | AD | Slowly progressive pure cerebellar ataxia w/mild tremor & mild hyperreflexia |
SPTBN2 | SCA5 (OMIM 600224) | AD | Slowly progressive pure cerebellar ataxia |
Unknown 1 | SCA20 | AD | Slowly progressive cerebellar ataxia w/abnormal phonation & dysarthria, & palatal tremor in two thirds of individuals. Minor pyramidal signs may also be seen. |
AD = autosomal dominant; MOI = mode of inheritance; SCA = spinocerebellar ataxia
- 1.
The locus for SCA20 lies within the pericentromeric region of chromosome 11; the gene is unknown. A 260-kb duplication of 11q12.2-11q12.3 has been proposed as the probable cause of SCA20 in the index family.
See the Hereditary Ataxia Overview for information on other types of inherited (genetic) ataxia.
Management
Management is supportive; a multidisciplinary approach is recommended.
Evaluations Following Initial Diagnosis
To establish the extent of disease and needs in an individual diagnosed with spinocerebellar ataxia type 11 (SCA11), the evaluations summarized in Table 4 (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 4.
System/Concern | Evaluation | Comment |
---|---|---|
Neurologic | Neurologic evaluation | Use SARA 1 to establish baseline |
Head MRI | Initial imaging to establish extent of cerebellar atrophy at disease presentation | |
Feeding evaluation | To evaluate for bulbar involvement that may require intervention, e.g., adjustment to dietary consistency to improve safe swallow | |
Speech & language therapy evaluation | If dysarthria is atypical or severe enough to cause communication problems | |
Physiotherapy & occupational therapy evaluation | To evaluate mobility, activities of daily living, & need for adaptive devices | |
Peripheral nervous system | Nerve conduction studies | Nerve conduction studies are recommended to exclude a coexisting neuropathy that may require further monitoring. |
Ophthalmologic | Ophthalmologic evaluation | To evaluate eye movement & for diplopia |
Other | Consultation w/clinical geneticist &/or genetic counselor |
- 1.
SARA = Scale for the Assessment and Rating of Ataxia
Treatment of Manifestations
Management is supportive; no disease-modifying treatments are known to date.
Table 5.
Manifestation Concern | Treatment | Considerations/Other |
---|---|---|
Ataxia |
| Consider adaptive devices (cane &/or wheelchair) & home adaptations to maintain/improve independent mobility. |
Weight control | To facilitate ambulation | |
Dysarthria & dysphagia | Speech & language therapy evaluation/treatment | To teach strategies to improve articulation & avoid aspiration |
Modify food consistency to reduce aspiration risk | Video esophagram may help define best consistency. | |
Peripheral neuropathy | Ankle-foot orthotics | Ensure good foot care & foot health w/regular review by podiatrist. |
Diplopia | Ophthalmologic consultation | Prism glasses can be helpful. |
OT = occupational therapy; PT = physical therapy
Surveillance
Table 6.
System/Concern | Evaluation | Frequency |
---|---|---|
Ataxia | Neurologic evaluation | Annually |
PT & OT | Ideally, in the context of a multidisciplinary setting w/more intensive follow up if needed | |
Dysarthria & dysphagia | Evaluation w/speech & language therapist | Follow up dependent on severity & requirements |
Ophthalmoplegia & diplopia | Ophthalmology | Follow up dependent on severity & requirements |
OT = occupational therapy; PT = physical therapy
Evaluation of Relatives at Risk
See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.
Therapies Under Investigation
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.